tiprankstipranks
Analyst Profile
Followed by 1,201 other investors
.
David Nierengarten

David Nierengarten

Wedbush
Wall Street Analyst
Ranked #295 out of 8,047 Analysts on TipRanks (#389 out of 21,521 overall experts)

Success Rate

47%
188 out of 398 Profitable Transactions

Average Return

18.60%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark
If you copied David Nierengarten's ratings since 2013 and opened each position for the duration of 1 Year:
47.24% of your transactions would have been profitable with an average return of 18.6%

Stock Rating Distribution

535Ratings
76.82% Buy
19.07% Hold
4.11% Sell
Distribution of David Nierengarten's ratings

Additional Information

Main Sector:Healthcare
Geo Coverage:
United StatesUS Market
United KingdomUK Market

Best Rating

Stock:
Bluebird bio Inc
(BLUE)
Rating Type:Buy
Dates:May 21, 2014 - May 21, 2015
Gain:643.80%
The most profitable rating made by David Nierengarten

David Nierengarten's Stock Coverage

Company Name
Date
Position
Action
Price Target
Success Rate
Avg Return
No. of Ratings
Baxter International
Mar 22, 2013
Hold
Reiterated
0.00%
1
Oncternal Therapeutics
Aug 19, 2013
Hold
Downgraded
$2.00
(72.41% Upside)
0%
-75.30%
2
GENTY
Gentium
Dec 20, 2013
Hold
Downgraded
100%
+110.90%
2
Insmed
Mar 31, 2014
Sell
Reiterated
67%
+15.43%
3
DNDNQ
Dendreon Corp
Aug 15, 2014
Sell
Reiterated
100%
+53.02%
5
CASC
Cascadian Therapeutics
Oct 21, 2014
Buy
Initiated
100%
+36.30%
2
NPSP
NPS Pharma
Jan 25, 2015
Hold
Reiterated
89%
+70.21%
11
PCYC
Pharmacyclics
Mar 03, 2015
Hold
Downgraded
100%
+63.03%
6
Eiger Biopharmaceuticals
Apr 27, 2015
Hold
Downgraded
$45.00
(391.80% Upside)
100%
+78.80%
2
GEVA
Synageva
May 07, 2015
Hold
Downgraded
100%
+57.10%
6
List of latest recommendations made by David Nierengarten. Click to expand and see David Nierengarten's performance on a particular stock
Disclaimer: TipRanks collects ratings and price targets of analysts by scanning publicly available reports on financial websites and by receiving reports directly from the analysts or from our users. The information displayed and the Analyst Profile statistics might not be accurate, complete, or up to date. The analyst ratings provided are entirely at the sole responsibility of the of the source publication. TipRanks holds no liability over the analysts' information, price targets, ratings or opinions expressed on the site.
Are We Missing a Rating?
Send us the equity research you are getting and become a Power User
Learn More